Published in Semin Oncol on August 01, 1999
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A (2002) 2.32
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol (2010) 1.80
A dual role for ErbB2 signaling in cardiac trabeculation. Development (2010) 1.59
Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation (2011) 1.10
Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One (2012) 1.04
Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest (2000) 1.02
Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson (2008) 0.97
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice. Toxicol Appl Pharmacol (2008) 0.95
Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clin Res Cardiol (2012) 0.89
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer (2004) 0.88
The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. Bioimpacts (2013) 0.82
Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity? World J Radiol (2012) 0.82
Trastuzumab-associated cardiac events in the Persephone trial. Br J Cancer (2016) 0.81
The growth factor receptor ERBB2 regulates mitochondrial activity on a signaling time scale. J Biol Chem (2013) 0.78
Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev (2011) 0.78
Cardiotoxic drugs in breast cancer. J Natl Med Assoc (2004) 0.75
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol (2012) 1.81
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg (1990) 1.59
Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg (1986) 1.50
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Adriamycin cardiomyopathy--risk factors. Cancer (1977) 1.46
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol (1999) 1.45
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol (2010) 1.42
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Combination chemotherapy in adult desmoid tumors. Cancer (1993) 1.36
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res (1977) 1.36
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol (1997) 1.34
Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer (1999) 1.31
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol (1999) 1.29
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol (1984) 1.28
Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery (1994) 1.28
Doxorubicin-induced congestive heart failure in adults. Cancer (1985) 1.26
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (1993) 1.25
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. Cancer Treat Rep (1977) 1.21
Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA (1988) 1.20
Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther (1973) 1.19
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol (1994) 1.17
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol (2001) 1.17
Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol (1995) 1.15
Myxoid liposarcoma. Experience with chemotherapy. Cancer (1994) 1.13
Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer (1993) 1.09
Arterial occlusion: management of giant cell tumor and aneurysmal bone cyst. AJR Am J Roentgenol (1981) 1.09
Posterior-stabilized and cruciate-retaining total knee replacement: a randomized study. Clin Orthop Relat Res (2001) 1.05
A minimal motor domain from chicken skeletal muscle myosin. J Biol Chem (1995) 1.05
Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer (1996) 1.05
The psychosocial impact of systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (1984) 1.04
Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol (1997) 1.04
Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors. Cancer (1990) 1.03
Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer (2001) 1.02
Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 1.01
Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.01
Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol (1982) 1.00
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol (1995) 1.00
Endocarditis caused by beta-lactamase-producing Haemophilus influenzae. South Med J (1987) 0.99
Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer (1994) 0.99
Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol (1994) 0.99
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol (1992) 0.99
Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann Thorac Surg (1991) 0.98
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep (1979) 0.98
Ectopic production of the beta-subunit of human chorionic gonadotropin in osteosarcoma. Arch Pathol Lab Med (1989) 0.98
Primary extraskeletal osteosarcoma--experience with chemotherapy. J Natl Cancer Inst (1995) 0.97
Sarcoma of the stomach: clinicopathologic study of 43 cases. J Surg Oncol (1980) 0.97
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol (1995) 0.97
A phase II trial of taxol in metastatic melanoma. Cancer (1990) 0.97
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol (2000) 0.96
A 15-year experience with chemotherapy of patients with paraganglioma. Cancer (1995) 0.96
The natural history of resectable metastatic melanoma (Stage IVA melanoma). Cancer (1982) 0.96
Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res (1983) 0.95
Primary soft tissue sarcoma of the breast. Curr Treat Options Oncol (2001) 0.95
The natural history of metastatic synovial sarcoma: experience of the Southwest Oncology group. Clin Orthop Relat Res (1982) 0.94
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res (1984) 0.94
Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor. Ann Intern Med (1990) 0.93
Recovery of sperm production after chemotherapy for osteosarcoma. Cancer (1989) 0.92
Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol (1982) 0.92
A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol (1989) 0.91
Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol (1995) 0.91
Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep (1980) 0.90
Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Magn Reson Imaging Clin N Am (1995) 0.90
Cytology of malignant melanoma of soft parts: fine-needle aspirates and exfoliative specimens. Diagn Cytopathol (1993) 0.90
Giant vegetation due to Staphylococcus aureus endocarditis simulating left atrial myxoma. Am Heart J (1986) 0.90
Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharmacol (1981) 0.89
Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs (1998) 0.89
Mesosomes in m-tyrosine-inhibited Bacillus thuringiensis. J Bacteriol (1967) 0.88
Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin Pharmacol Ther (1973) 0.88
Intraarterial management of giant-cell tumors of the spine in children. Pediatr Radiol (1982) 0.88
Computerized tomographic finding of saddle pulmonary embolism is associated with high mortality in cancer patients. Intern Med J (2009) 0.87
Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. Cancer (1983) 0.87
Postoperative atrial fibrillation in cancer surgery: preoperative risks and clinical outcome. J Surg Oncol (1992) 0.87
Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. Cancer Res (1978) 0.87
Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res (1982) 0.87
Pharmacokinetics of adriamycin (NSC-123127) in patients with sarcomas. Cancer Chemother Rep (1974) 0.87
Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest New Drugs (1985) 0.87
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr (1993) 0.87
Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5. Cancer Res (1985) 0.87
Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res (1985) 0.86
Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. Cancer Treat Rep (1981) 0.86
Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma? J Clin Oncol (1987) 0.86
The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma. Cancer (1978) 0.86
Chemotherapy for metastatic Merkel cell carcinoma. Review of the M.D. Anderson Hospital's experience. Cancer (1988) 0.86
Arterial embolism of tumor causing fatal organ infarction. Arch Intern Med (1974) 0.86
Chemotherapy for sarcoma of the stomach. Cancer Treat Rep (1979) 0.86
Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol (1984) 0.85
Infective endocarditis of a bicuspid aortic valve caused by Hansenula anomala. Am J Med (1987) 0.85
Myocardial infarction due to intracoronary thrombi without significant coronary artery disease in systemic lupus erythematosus. Chest (1991) 0.85